U.S. Markets open in 5 hrs

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1200+0.0300 (+2.75%)
At close: 04:00PM EDT
1.0800 -0.04 (-3.57%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0900
Bid0.0000 x 3200
Ask0.0000 x 3100
Day's Range1.0600 - 1.1500
52 Week Range1.0400 - 5.2400
Avg. Volume3,349,873
Market Cap443.325M
Beta (5Y Monthly)2.02
PE Ratio (TTM)560.00
EPS (TTM)0.0020
Earnings DateAug 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.57
  • GlobeNewswire

    Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference

    DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. H.C. Wainwright 24th Annual Global Investment Conference (September 12-14th, 2022; New York, New York) Date/Time: September 12, 2022, 9:00 a.m. ET/ 1:00 p.m. GMT+1 Webcast: https://journey.ct

  • Benzinga

    Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers

    Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking. In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo. Related: Amarin's New Vascepa Data Shows Significant Reduction

  • GlobeNewswire

    New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

    -- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- -- Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 28, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new RED